Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ultevursen - ProQR Therapeutics

Next Previous
X
Search
Drug Profile

Ultevursen - ProQR Therapeutics

Alternative Names: QR-421; QR-421a; QRX-421

Latest Information Update: 09 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ProQR Therapeutics
  • Developer Laboratoire Thea; ProQR Therapeutics
  • Class Antisense RNA; Eye disorder therapies; Oligonucleotides
  • Mechanism of Action RNA interference; USH2A protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Usher syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Retinitis pigmentosa
  • Phase II Usher syndromes

Most Recent Events

  • 04 Oct 2024 Laboratoires Thea plans to initiated a phase II trial for Retinitis Pigmentosa and Usher Syndrome Type 2 (Intravitreal) (NCT06627179)
  • 08 Dec 2023 ProQR completes the divestment of sepofarsen and ultevursen to Laboratoires Théa to continue the development of these programs for patients with LCA10 and Usher syndrome
  • 27 Sep 2023 ProQR Therapeutics terminates its agreement with Laboratoires Thea

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top